Oslo, Norway, 14 September 2021

Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Erik Skullerud
as Chief Executive Officer (CEO). He will take up the position on 20 September
2021 and will be based in the company's office in Zug, Switzerland, splitting
his time between Zug and Nordic Nanovector's head office in Oslo.

Mr Skullerud joins the Company from Element Consulting GmbH, a globally focused
boutique advisory and consultancy specializing in the life science industry
where he was co-founder and managing partner.

Prior to establishing Element Consulting, Mr Skullerud spent 25 years in the
biopharma industry with increasing responsibility in global sales and marketing
management roles. This included more than 15 years at Amgen, where his most
recent role was as Marketing Director Europe Oncology/ Hematology. Prior to
that, he worked for Bayer Pharma for seven years, most recently as Product Group
Manager for Cardiovascular/ Diabetes Scandinavia.

Mr Skullerud has launched numerous highly innovative products in therapeutic
areas such as oncology, haematology, cardiology, and nephrology and he has
significant business management exposure to EU, Asian and US markets. As a
consultant he has worked with some of the world's top pharma and biotech
companies as well as small, highly specialised start-ups on projects ranging
from corporate strategy, through early to mid-stage launch and commercialization
to late-stage life cycle projects.

Mr Skullerud is a Norwegian national and a Swiss resident. He has a BSc,
Marketing, Finance and Management from Gothenburg Business School, University of
Gothenburg and has been a Guest Lecturer, INSEAD MBA Program, Paris, France.

Jan H. Egberts, Chairman of Nordic Nanovector's Board of Directors, said: "I am
very pleased that Erik has agreed to join Nordic Nanovector. His commercial
leadership experience combined with his knowledge of the oncology/haematology
space will be vital as we evolve into a larger and more valuable business based
on maximising the commercial potential of Betalutin®. I would like to thank
Malene Brondberg for stepping up to the role of Interim CEO over the last few
months, a period when the company has made good progress in delivering on its
key objectives. Malene will continue in her role as CFO."

Mr Skullerud added: "I am very much looking forward to this new role at Nordic
Nanovector. I believe my experience from around the world in strategy,
commercialisation, and sales and marketing can help the company achieve the next
important stage of its development as we work to bring Betalutin® to patients
for the first time, a key step in realising the wider value of the business."

When joining Nordic Nanovector, Mr Skullerud will be granted 350,000 PSUs
(performance share units).

For further information about the PSUs and the related warrants, see page 28 in
the company's annual report for 2020.

For further information, please contact:

IR enquiries

Jan H. Egberts, Chairman of Nordic Nanovector
Tel: +31 614672518
Email: janegberts@aol.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)
Tel: +44 203 926 8535
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found
at www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url
=
http%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrav
a
.com%7Ca91a12b7fd1942b911c508d9639fcaf4%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7
C
0%7C637650361008661079%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luM
z
IiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=YpIUKimx78JX14KG4Tcg6D3vx2RnTkqhO2
n
06S0%2B8ag%3D&reserved=0).

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management's current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector's business, financial condition and results
of operations. The terms "anticipates", "assumes", "believes", "can", "could",
"estimates", "expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector's
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector's potential market and
industry, Nordic Nanovector's freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.